Assertio Holdings Stock Forecast for 2023 - 2025 - 2030
Updated on 04/26/2024
Assertio Holdings Stock Forecast and Price Target
Assertio Holdings has an average price target of $3.00 recently offered by two notable experts for 2024, which would represent a potential upside of approximately 279.75% from the last closing price in April, 2024 if reached. This potential increase is based on a high estimate of $3.00 and a low estimate of $3.00. If you are interested in ASRT stock, it is important to also consider its competitors.
279.75% Upside
Assertio Holdings Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, Assertio Holdings's Price has decreased from $0.31 to $0.00 – a 100.00% drop. In the next year, analysts expect Fair Value to reach $1.26 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£120.26 | Buy/Sell | £165.99 | 34.56% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$25.26 | Buy/Sell | $32.87 | 20.74% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$269.38 | Buy/Sell | $303.65 | 17.77% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$65.27 | Buy/Sell | $87.82 | 22.57% |
| 4568 Stock Forecast | Daiichi Sankyo Company | Buy |
4
|
¥4.77k | Buy/Sell | ¥5.24k | 21.70% |
Assertio Holdings Revenue Forecast for 2023 - 2025 - 2030
Assertio Holdings's Revenue has increased by 40.70% In the last three years, going from $108.08M to $152.07M. In the next year, analysts expect Revenue to reach $214.20M – an increase of 40.86%. For the next seven years, the forecast is for Revenue to grow by 27.99%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
5
|
¥4.09k | Buy/Sell | ¥4.74k | 11.25% |
| JAZZ Stock Forecast | Jazz Pharmaceuticals | Outperform |
14
|
$107.43 | Buy/Sell | $188.32 | 76.86% |
| HLUN A Stock Forecast | H. Lundbeck A/S | Outperform |
18
|
kr32.56 | Buy/Sell | kr190.00 | 12.10% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| INSM Stock Forecast | Insmed | Buy |
11
|
$24.92 | Buy/Sell | $41.42 | 68.54% |
| PBH Stock Forecast | Prestige Consumer Healthcare | Outperform |
16
|
$70.14 | Buy/Sell | $71.50 | 6.22% |
| BHC Stock Forecast | Bausch Health Companies | Hold |
15
|
$8.62 | Buy/Sell | $9.50 | 10.21% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Buy |
14
|
$8.08 | Buy/Sell | $17.83 | 110.40% |
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$40.83 | Buy/Sell | $69.00 | 51.85% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$29.31 | Buy/Sell | $41.00 | 36.47% |
Assertio Holdings EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Assertio Holdings's EBITDA has grown from $-16.28M to $44.27M – a 371.93% increase. Next year, analysts are expecting EBITDA to reach $92.59M – an increase of 109.15%. Over the next seven years, the forecast is for EBITDA to grow by 142.11%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ANIP Stock Forecast | ANI Pharmaceuticals | Buy |
13
|
$64.95 | Buy/Sell | $69.75 | 23.17% |
| COPN Stock Forecast | Cosmo Pharmaceuticals N.V. | Buy |
12
|
CHF72.10 | Buy/Sell | CHF76.55 | 30.47% |
| PCRX Stock Forecast | Pacira BioSciences | Outperform |
16
|
$25.50 | Buy/Sell | $47.90 | 76.47% |
Assertio Holdings EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Assertio Holdings's EBIT has grown by 137.56%, rising from $-42.71M to $16.04M. For next year, analysts predict EBIT of $53.89M, which would mean an increase of 235.97%. Over the next seven years, experts predict that Assertio Holdings's EBIT will grow at a rate of 487.03%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| COLL Stock Forecast | Collegium Pharmaceutical | Outperform |
11
|
$35.84 | Buy/Sell | $37.75 | 11.61% |
| AQST Stock Forecast | Aquestive Therapeutics | Buy |
0
|
$3.93 | Buy/Sell | $6.33 | 129.01% |
| CHRS Stock Forecast | Coherus BioSciences | Outperform |
6
|
$1.93 | Buy/Sell | $10.86 | 314.51% |
Assertio Holdings EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, Assertio Holdings's EPS has decreased from $0.11 to $0.00 – a 100.00% drop. In the next year, analysts expect EPS to reach $0.45 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABEO Stock Forecast | Abeona Therapeutics | Buy |
8
|
$3.19 | Buy/Sell | $21.25 | 432.92% |
| NKTR Stock Forecast | Nektar Therapeutics | Hold |
11
|
$1.32 | Buy/Sell | $2.75 | -24.24% |
| EBS Stock Forecast | Emergent BioSolutions | Outperform |
16
|
$1.95 | Buy/Sell | $5.00 | 156.41% |
.jpg)